CSPC Pharmaceutical Group Partners with AstraZeneca for AI-Driven Drug Discovery

CSPC Pharmaceutical Group ( (HK:1093) ) just unveiled an announcement.

CSPC Pharmaceutical Group has entered into a strategic research collaboration with AstraZeneca to discover and develop novel oral small molecule candidates using CSPC’s AI-driven drug discovery platform. This agreement allows AstraZeneca to potentially license these candidates for global development and commercialization, with CSPC receiving significant upfront and milestone payments, as well as potential royalties, indicating a substantial impact on CSPC’s operations and industry positioning.

The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.80 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.

More about CSPC Pharmaceutical Group

CSPC Pharmaceutical Group is a company incorporated in Hong Kong, operating in the pharmaceutical industry. The company focuses on the discovery and development of novel drug candidates using an AI-driven drug discovery platform.

Average Trading Volume: 199,811,387

Technical Sentiment Signal: Buy

Current Market Cap: HK$101.5B

Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.